Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

References

• Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982. doi:10.1016/j.jacc.2020.11.010
   PubMed Web of Science ®Google Scholar
• WHO Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed June 10, 2024.
   Google Scholar
• Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21:401. doi:10.1186/s12889-021-10429-0
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele’ V. Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol. 2008;59(8–9):701–706. doi:10.1007/s00228-003-0634-y
   Google Scholar
• Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024–2034. doi:10.1056/NEJMra2115011
   PubMed Web of Science ®Google Scholar
• Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069–1084. doi:10.1056/NEJMoa2306963
   PubMedGoogle Scholar
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
   PubMed Web of Science ®Google Scholar
• Ozawa S, Shankar R, Leopold C, et al. Access to medicines through health systems in low- and middle-income countries. Health Policy Plan. 2019;34(Supplement_3):iii1–iii3. doi:10.1093/heapol/czz119
   PubMedGoogle Scholar
• Gaziano TA, Bitton A, Anand S, et al. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115. doi:10.1016/j.cpcardiol.2009.10.002
   PubMed Web of Science ®Google Scholar
• Granger CB, Pocock SJ, Gersh BJ. The need for new clinical trials of old cardiovascular drugs. Nat Rev Cardiol. 2022;20(2):71–72. doi:10.1038/s41569-022-00819-1
   Web of Science ®Google Scholar
• Samuel SM, Varghese E, Kubatka P, et al. Metformin: the Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules. 2019;9(12):846. doi:10.3390/biom9120846
   PubMed Web of Science ®Google Scholar
• Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021;2:718942. doi:10.3389/fendo.2021.718942
   Google Scholar
• Triggle CR, Mohammed I, Bshesh K, et al. Metformin: is it a drug for all reasons and diseases? Metabolism. 2022;133:155223. doi:10.1016/j.metabol.2022.155223
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi:10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. European Journal of Preventive Cardiology. 2019;26(2_suppl):25–32. doi:10.1177/2047487319878371
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844. doi:10.1001/jama.1994.03510350050036
   PubMed Web of Science ®Google Scholar
• Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med]. 2010;25(8):853–858. doi:10.1007/s11606-010-1340-y
   PubMed Web of Science ®Google Scholar
• Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56–62. doi:10.1016/j.amjcard.2011.03.004
   PubMed Web of Science ®Google Scholar
• Perez MV, Wang PJ, Larson JC, et al. Risk factors for atrial fibrillation and their population burden in postmenopausal women: the Women’s Health Initiative Observational Study. Heart. 2013;99(16):1173–1178. doi:10.1136/heartjnl-2013-303798
   PubMed Web of Science ®Google Scholar
• Qi W, Zhang N, Korantzopoulos P, et al. Serum glycated hemoglobin level as a predictor of atrial fibrillation: a systematic review with meta-analysis and metaregression. PLoS One. 2017;12(3):e0170955. doi:10.1371/journal.pone.0170955
   Google Scholar
• Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J Cardiovasc Dis Res. 2010;1(1):10–11. doi:10.4103/0975-3583.59978
   PubMedGoogle Scholar
• Wang A, Green JB, Halperin JL, et al. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(8):1107–1115. doi:10.1016/j.jacc.2019.07.020
   PubMed Web of Science ®Google Scholar
• Xiong Z, Liu T, Tse G, et al. A machine learning aided systematic review and meta-analysis of the relative risk of atrial fibrillation in patients with diabetes mellitus. Front Physiol. 2018;9:835. doi:10.3389/fphys.2018.00835
   Web of Science ®Google Scholar
• Davis TME, Parsons RW, Broadhurst RJ, et al. Arrhythmias and Mortality After Myocardial Infarction in Diabetic Patients: relationship to diabetes treatment. Diabetes Care. 1998;21(4):637–640. doi:10.2337/diacare.21.4.637
   Web of Science ®Google Scholar
• Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13(1):1–8. doi:10.1186/s12933-014-0123-x
   Google Scholar
• Shi W, Zhang W, Zhang D, et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: a network meta-analysis. Heart Rhythm. 2021;18(7):1090–1096. doi:10.1016/j.hrthm.2021.03.007
   PubMed Web of Science ®Google Scholar
• Chen HY, Yang FY, Jong GP, Liou YS. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients. Eur J Clin Invest. 2017;47(5):388–393. doi:10.1111/eci.12754
   PubMed Web of Science ®Google Scholar
• Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One. 2018;13(8):e0197245. doi:10.1371/journal.pone.0197245
   PubMed Web of Science ®Google Scholar
• Ostropolets A, Elias PA, Reyes MV, et al. Metformin Is Associated with a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared to Sulfonylureas: an Observational Study. Circ Arrhythm Electrophysiol. 2021;14(3):e009115. doi:10.1161/CIRCEP.120.009115
   Web of Science ®Google Scholar
• Kim S, Park SY, Kim B, et al. Association between antidiabetic drugs and the incidence of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in South Korea. Diabet Res Clin Pract. 2023:198. doi:10.1016/j.diabres.2023.110626
   Web of Science ®Google Scholar
• Iqbal A, Tekin Z, Kattan MW, et al. Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes. J Diabetes Complications. 2022;36(11):108315. doi:10.1016/j.jdiacomp.2022.108315
   Web of Science ®Google Scholar
• Zhou J, Zhang G, Chang C, et al. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. Acta Diabetol. 2022;59(5):697–709. doi:10.1007/s00592-021-01841-4
   Web of Science ®Google Scholar
• Lal JC, Mao C, Zhou Y, et al. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Reports Med. 2022;3(10):100749.
   Google Scholar
• Vinciguerra M, Olier I, Ortega-Martorell S, et al. New use for an old drug: metformin and atrial fibrillation. Cell Reports Med. 2022;3(12):100875. doi:10.1016/j.xcrm.2022.100875
   Google Scholar
• Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol. 2020;19(1):198. doi:10.1186/s12933-020-01176-4
   PubMed Web of Science ®Google Scholar
• Li JZ, Li YR. Cardiovascular Protection by Metformin: latest Advances in Basic and Clinical Research. Cardiology. 2023;148(4):374–384. doi:10.1159/000531432
   Web of Science ®Google Scholar
• Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008;22(3):215–224. doi:10.1007/s10557-008-6092-0
   Web of Science ®Google Scholar
• Triggle CR, Marei I, Ye K, et al. Repurposing Metformin for Vascular Disease. Curr Med Chem. 2023;30(35):3955–3978. doi:10.2174/0929867329666220729154615
   Web of Science ®Google Scholar
• Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(2):116–124. doi:10.1016/S2213-8587(13)70152-9
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125. doi:10.1161/CIRCULATIONAHA.105.595140
   PubMed Web of Science ®Google Scholar
• Nayak S, Natarajan B, Pai RG. Etiology, Pathology, and Classification of Atrial Fibrillation. Int J Angiol. 2020;29(2):65–71. doi:10.1055/s-0040-1705153
   Web of Science ®Google Scholar
• Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. doi:10.1056/NEJM199602293340906
   PubMed Web of Science ®Google Scholar
• Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8):1105–1107. doi:10.1172/JCI14178
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008;5(3):157–167. doi:10.3132/dvdr.2008.027
   PubMed Web of Science ®Google Scholar
• Khilnani G. Metformin: a Reflection on My Journey as Antidiabetic Drug. GAIMS Journal of Medical Sciences. 2023;3(2):34–40.
   Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253–270. doi:10.1042/CS20110386
   PubMed Web of Science ®Google Scholar
• Bosi E. Metformin—The Gold Standard in Type 2 Diabetes: what Does the Evidence Tell Us? Diabetes Obesity Metab. 2009;11,3–8. doi:10.1111/j.1463-1326.2008.01031.x
   Web of Science ®Google Scholar
• Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369. doi:10.1172/JCI40671
   PubMed Web of Science ®Google Scholar
• Gu S, Tang Z, Shi L, et al. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value Heal Reg Issues. 2015;6:84–88. doi:10.1016/j.vhri.2015.03.012
   Google Scholar
• Glossmann HH, Lutz OMD. Pharmacology of metformin - An update. Eur J Pharmacol. 2019;865:172782. doi:10.1016/j.ejphar.2019.172782
   PubMed Web of Science ®Google Scholar
• He L. Metformin and Systemic Metabolism. Trends Pharmacol Sci. 2020;41(11):868–881. doi:10.1016/j.tips.2020.09.001
   PubMed Web of Science ®Google Scholar
• LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2022;42(1):77–96. doi:10.1210/endrev/bnaa023
   Web of Science ®Google Scholar
• Corcoran C, Jacobs TF. Metformin. 2023. Treasure Island (FL): StatPearls Publishing; 2024.
   Google Scholar
• Johnson NP. Metformin use in women with polycystic ovary syndrome. Annals of Translational Med. 2014;2(6):56. doi:10.3978/j.issn.2305-5839.2014.04.15
   Google Scholar
• Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307–322. doi:10.1042/BJ20150497
   PubMed Web of Science ®Google Scholar
• Samuel SM, Varghese E, Büsselberg D. Therapeutic Potential of Metformin in COVID-19: reasoning for Its Protective Role. Trends Microbiol. 2021;29(10):894–907. doi:10.1016/j.tim.2021.03.004
   Web of Science ®Google Scholar
• Salvatore T, Pafundi PC, Galiero R, et al. Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects? Biomedicines. 2020a;9(1):3. doi:10.3390/biomedicines9010003
   PubMed Web of Science ®Google Scholar
• Salvatore T, Pafundi PC, Morgillo F, et al. Metformin: an old drug against old age and associated morbidities. Diabet Res Clin Pract. 2020b;160:108025. doi:10.1016/j.diabres.2020.108025
   PubMed Web of Science ®Google Scholar
• Varghese E, Samuel SM, Liskova A, et al. Diabetes and coronavirus (SARS-CoV-2): molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathog. 2021;17(6):e1009634. doi:10.1371/journal.ppat.1009634
   Web of Science ®Google Scholar
• Martin DE, Cadar AN, Bartley JM. Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults. Frontiers in Aging. 2023;4:1–10.
   Google Scholar
• Zimmerman SC, Ferguson EL, Choudhary V, et al. Metformin Cessation and Dementia Incidence. JAMA Network Open. 2023;6(10):e2339723. doi:10.1001/jamanetworkopen.2023.39723
   Web of Science ®Google Scholar
• OHY Y, Suissa S. Metformin and Cancer: solutions to a Real-World Evidence Failure. Diabetes Care. 2023;46(5):904–912. doi:10.2337/dci22-0047
   Web of Science ®Google Scholar
• Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327(20):1963–1973. doi:10.1001/jama.2022.6147
   Web of Science ®Google Scholar
• Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665–2673. doi:10.2337/dc12-0788
   PubMed Web of Science ®Google Scholar
• Iudici M, Porcher R, Riveros C, et al. Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review. Ann Rheum Dis. 2019;78(4):562–569. doi:10.1136/annrheumdis-2018-214544
   Web of Science ®Google Scholar
• Luo F, Das A, Chen J, et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019;18(1):54. doi:10.1186/s12933-019-0860-y
   PubMedGoogle Scholar
• Zheng J, Xu M, Yang Q, et al. Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study. EBioMedicine. 2023;96:104803. doi:10.1016/j.ebiom.2023.104803
   Web of Science ®Google Scholar
• Rena G, Lang CC. Repurposing Metformin for Cardiovascular Disease. Circulation. 2018;137(5):422–424. doi:10.1161/CIRCULATIONAHA.117.031735
   PubMed Web of Science ®Google Scholar
• Fetro C, Scherman D. Drug repurposing in rare diseases: myths and reality. Therapie. 2020;75(2):157–160. doi:10.1016/j.therap.2020.02.006
   Web of Science ®Google Scholar
• Jacob S, Knoll S, Huhn C, et al. Effects of guanylurea, the transformation product of the antidiabetic drug metformin, on the health of brown trout (Salmo trutta f. fario). PeerJ. 2019;7:e7289. doi:10.7717/peerj.7289
   Web of Science ®Google Scholar
• Chaignaud P, Gruffaz C, Borreca A, et al. A Methylotrophic Bacterium Growing with the Antidiabetic Drug Metformin as Its Sole Carbon, Nitrogen and Energy Source. Microorganisms. 2022;10(11):2302. doi:10.3390/microorganisms10112302
   Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195–202. doi:10.1007/BF00562061
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–246. doi:10.1111/j.1365-2125.1981.tb01206.x
   PubMed Web of Science ®Google Scholar
• Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837–850. doi:10.1097/FPC.0b013e32834c0010
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98. doi:10.2165/11534750-000000000-00000
   PubMed Web of Science ®Google Scholar
• Gong L, Goswami S, Giacomini KM, et al. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(11):820–827. doi:10.1097/FPC.0b013e3283559b22
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359–371. doi:10.2165/00003088-199630050-00003
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302(2):510–155. doi:10.1124/jpet.102.034140
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, et al. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9(4):415–422. doi:10.2217/14622416.9.4.415
   PubMed Web of Science ®Google Scholar
• Liang X, Giacomini KM. Transporters Involved in Metformin Pharmacokinetics and Treatment Response. J Pharm Sci. 2017;106(9):2245–2250. doi:10.1016/j.xphs.2017.04.078
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683–693. doi:10.1002/cpt1978246683
   PubMed Web of Science ®Google Scholar
• Kajbaf F, De Broe ME, Lalau JD. Therapeutic Concentrations of Metformin: a Systematic Review. Clin Pharmacokinet. 2016;55(4):439–459. doi:10.1007/s40262-015-0323-x
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174. doi:10.1172/JCI13505
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646. doi:10.1126/science.1120781
   PubMed Web of Science ®Google Scholar
• Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43(2):117–120. doi:10.1038/ng.735.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Cufí S, Oliveras-Ferraros C, et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging. 2011;3(11):1063–1077. doi:10.18632/aging.100407
   Google Scholar
• Meng S, Cao J, He Q, et al. Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J Biol Chem. 2015;290(6):3793–3802. doi:10.1074/jbc.M114.604421
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–1305. doi:10.1136/bmj.38415.708634.F7
   PubMed Web of Science ®Google Scholar
• Yee SW, Chen L, Giacomini KM. The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet. 2012;44(4):359–360. doi:10.1038/ng.2236
   PubMed Web of Science ®Google Scholar
• Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21(20):2644–2658. doi:10.1101/gad.435107
   PubMed Web of Science ®Google Scholar
• Arunachalam G, Samuel SM, Marei I, et al. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol. 2014;171(2):523–535. doi:10.1111/bph.12496
   PubMed Web of Science ®Google Scholar
• Zhan Y-Y, Chen Y, Zhang Q, et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nature Chemical Biology. 2012;8(11):897–904. doi:10.1038/nchembio.1069
   Web of Science ®Google Scholar
• Venu VKP, Saifeddine M, Mihara K, et al. Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). Mol Pharmacol. 2021;100(5):428–455. doi:10.1124/molpharm.120.000148
   PubMed Web of Science ®Google Scholar
• El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–228. doi:10.1074/jbc.275.1.223
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;3.
   Google Scholar
• Bridges HR, Blaza JN, Yin Z, et al. Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides. Science. 2023;379(6630):351–357. doi:10.1126/science.ade3332
   Web of Science ®Google Scholar
• Timmins P, Donahue S, Meeker J, et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721–729. doi:10.2165/00003088-200544070-00004
   PubMed Web of Science ®Google Scholar
• Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol. 1991;43(6):442–444. doi:10.1111/j.2042-7158.1991.tb03507.x
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57. doi:10.3109/00498259409043220
   PubMed Web of Science ®Google Scholar
• Kinaan M, Ding H, Triggle CR. Metformin: an Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med Princ Pract. 2015;24(5):401–415. doi:10.1159/000381643
   PubMed Web of Science ®Google Scholar
• He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159–162. doi:10.1016/j.cmet.2015.01.003
   PubMed Web of Science ®Google Scholar
• Fontaine E. Metformin-Induced Mitochondrial Complex I Inhibition: facts, Uncertainties, and Consequences. Front Endocrinol (Lausanne). 2018;9:753. doi:10.3389/fendo.2018.00753
   PubMed Web of Science ®Google Scholar
• Di Magno L, Di Pastena F, Bordone R, et al. The Mechanism of Action of Biguanides: new Answers to a Complex Question. Cancers (Basel). 2022;14. doi:10.3390/cancers14133220
   Web of Science ®Google Scholar
• Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–262. doi:10.1038/nrm3311
   PubMed Web of Science ®Google Scholar
• Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24:255–272. doi:10.1038/s41580-022-00547-x
   Web of Science ®Google Scholar
• Cantó C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20(2):98–105. doi:10.1097/MOL.0b013e328328d0a4
   PubMed Web of Science ®Google Scholar
• Krausova L, Stejskalova L, Wang H, et al. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol. 2011;82(11):1771–1780. doi:10.1016/j.bcp.2011.08.023
   PubMed Web of Science ®Google Scholar
• McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. doi:10.1007/s00125-015-3844-9
   PubMed Web of Science ®Google Scholar
• Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443(3):285–289. doi:10.1016/s0014-5793(98)01705-0
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601–605. doi:10.1038/21224
   PubMed Web of Science ®Google Scholar
• Morrow VA, Foufelle F, Connell JM, et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem. 2003;278(34):31629–31639. doi:10.1074/jbc.M212831200
   Web of Science ®Google Scholar
• Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57(3):696–705. doi:10.2337/db07-1098
   PubMed Web of Science ®Google Scholar
• Driver C, Bamitale KDS, Kazi A, et al. Cardioprotective Effects of Metformin. J Cardiovasc Pharmacol. 2018;72(2):121–127. doi:10.1097/FJC.0000000000000599
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Nattrass M. Treatment--metformin. Baillieres Clin Endocrinol Metab. 1988;2(2):455–476. doi:10.1016/s0950-351x(88)80043-0
   Google Scholar
• Lkhagva B, Lee TW, Lin YK. Disturbed Cardiac Metabolism Triggers Atrial Arrhythmogenesis in Diabetes Mellitus: energy Substrate Alternate as a Potential Therapeutic Intervention. Cells. 2022;11(18):2915. doi:10.3390/cells11182915
   Web of Science ®Google Scholar
• Seyed Ahmadi S, Svensson AM, Pivodic A, et al. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9. doi:10.1186/s12933-019-0983-1
   PubMed Web of Science ®Google Scholar
• Tan X, Pan X, Wu X, et al. Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. Front Pharmacol. 2023;14:975880. doi:10.3389/fphar.2023.975880
   Web of Science ®Google Scholar
• Dowling RJO, Niraula S, Stambolic V, et al. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43. doi:10.1530/JME-12-0007
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Johnson N. Drugs for anovulatory infertility in polycystic ovary syndrome. BMJ. 2006;332(7556):1461–1462. doi:10.1136/bmj.332.7556.1461
   PubMedGoogle Scholar
• Jakubowicz D, Seppala M. Effects of Metformin on Hyperinsulinemia, Hyperandrogenism and Reproduction in Women with Polycystic Ovarian Syndrome. J Endocrinol Diabetes Obes. 2014;2(2):1034. doi:10.1016/j.jacc.2014.02.555
   Google Scholar
• Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77(3):520–525. doi:10.1016/s0015-0282(01)03202-2
   PubMed Web of Science ®Google Scholar
• Fougner KJ, Vanky E, Carlsen SM. Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study. Scand J Clin Lab Invest. 2008;68(8):771–776. doi:10.1080/00365510802254620
   PubMed Web of Science ®Google Scholar
• Legro RS. Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust. J Clin Endocrinol Metab. 2010;95(12):5199–5202. doi:10.1210/jc.2010-2301
   PubMed Web of Science ®Google Scholar
• Dunne F, Newman C, Alvarez-Iglesias A, et al. Early Metformin in Gestational Diabetes: a Randomized Clinical Trial. JAMA. 2023;330(16):1547–1556. doi:10.1001/jama.2023.19869
   PubMed Web of Science ®Google Scholar
• Wensink MJ, Lu Y, Tian L, et al. Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring: A Nationwide Cohort Study. Ann Intern Med. 2022;175(5):665–673. doi:10.7326/M21-4389
   PubMed Web of Science ®Google Scholar
• Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ. 2018;361:k2477. doi:10.1136/bmj.k2477
   PubMedGoogle Scholar
• Tarry-Adkins JL, Ozanne SE, Aiken CE. Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. Sci Rep. 2021;11(1):9240. doi:10.1038/s41598-021-88650-5
   PubMed Web of Science ®Google Scholar
• Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. BMJ Open Diabetes Res Care. 2022;10(1):e002363. doi:10.1136/bmjdrc-2021-002363
   PubMed Web of Science ®Google Scholar
• Vanky E, Zahlsen K, Spigset O, et al. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83(5):1575–1578. doi:10.1016/j.fertnstert.2004.11.051
   PubMed Web of Science ®Google Scholar
• Nguyen L, Chan SY, Teo AKK. Metformin from mother to unborn child - Are there unwarranted effects? EBioMedicine. 2018;35:394–404. doi:10.1016/j.ebiom.2018.08.047
   PubMed Web of Science ®Google Scholar
• Feig DS, Donovan LE, Zinman B, et al. MiTy Collaborative Group. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020:834–844. doi:10.1016/S2213-8587(20)30310-7
   Google Scholar
• Wang L, Hou Y, Meng D, et al. Vitamin B12 and Folate Levels During Pregnancy and Risk of Gestational Diabetes Mellitus: a Systematic Review and Meta-Analysis. Front Nutr. 2021;8:670289. doi:10.3389/fnut.2021.670289
   Web of Science ®Google Scholar
• Lee N, Hebert MF, Wagner DJ, et al. Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy. Mol Pharmacol. 2018;94(4):1125–1131. doi:10.1124/mol.118.112482
   Web of Science ®Google Scholar
• Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol. 2005;105(6):1437–1441. doi:10.1097/01.AOG.0000163249.65810.5b
   Web of Science ®Google Scholar
• George MM, Copeland KC. Current Treatment Options for Type 2 Diabetes Mellitus in Youth: today’s Realities and Lessons from the TODAY Study. Curr Diab Rep. 2013;13:72–80. doi:10.1007/s11892-012-0334-z
   PubMed Web of Science ®Google Scholar
• Priya G, Kalra S. Metformin in the management of diabetes during pregnancy and lactation. Drugs Context. 2018;7:212523. doi:10.7573/dic.212523
   Google Scholar
• Niemuth NJ, Klaper RD. Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. Chemosphere. 2015;135:38–45. doi:10.1016/j.chemosphere.2015.03.060
   PubMed Web of Science ®Google Scholar
• Niemuth NJ, Klaper RD. Low-dose metformin exposure causes changes in expression of endocrine disruption-associated genes. Aquat Toxicol. 2018;195:33–40. doi:10.1016/j.aquatox.2017.12.003
   PubMed Web of Science ®Google Scholar
• Alla LNR, Monshi M, Siddiqua Z, et al. Detection of endocrine disrupting chemicals in Danio rerio and Daphnia pulex: step-one, behavioral screen. Chemosphere. 2021;271:129442. doi:10.1016/j.chemosphere.2020.129442
   Web of Science ®Google Scholar
• Suhre K, Stephan N, Zaghlool S, et al. Matching Drug Metabolites from Non-Targeted Metabolomics to Self-Reported Medication in the Qatar Biobank Study. Metabolites. 2022;12(3):249. doi:10.3390/metabo12030249
   Web of Science ®Google Scholar
• Petrie JR, Chaturvedi N, Ford I, et al. Metformin in adults with type 1 diabetes: d esign and Methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): a n international multicentre trial. Diabetes Obesity Metab. 2017;19(4):509–516. doi:10.1111/dom.12840
   Web of Science ®Google Scholar
• Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609. doi:10.1016/S2213-8587(17)30194-8
   PubMed Web of Science ®Google Scholar
• Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. J Res Med Sci. 2014;19(7):658–664.
   PubMed Web of Science ®Google Scholar
• McGovern A, Tippu Z, Hinton W, et al. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta analysis. Diabetes Obesity Metab. 2018;20(4):1040–1043. doi:10.1111/dom.13160
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z
   PubMed Web of Science ®Google Scholar
• Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. doi:10.1111/dom.12854
   PubMed Web of Science ®Google Scholar
• Wong AKF, Howie J, Petrie JR, et al. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci. 2009;116(8):607–620. doi:10.1042/CS20080066
   PubMed Web of Science ®Google Scholar
• Bell DSH. Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes Obes Metab. 2022;24(8):1423–1428. doi:10.1111/dom.14734
   Web of Science ®Google Scholar
• Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227–1231. doi:10.2337/diacare.23.9.1227
   PubMed Web of Science ®Google Scholar
• Sayedali E, Yalin AE, Yalin S. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes. World J Diabetes. 2023;14(5):585–593. doi:10.4239/wjd.v14.i5.585
   Web of Science ®Google Scholar
• Wåhlén A, Haenni A, Johansson HE. Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus? Diabetes Metab Syndr Obes. 2017;10:151–154. doi:10.2147/DMSO.S131340
   PubMed Web of Science ®Google Scholar
• Chowdhury M, Nevitt S, Eleftheriadou A, et al. Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis. BMJ Open Diabetes Res Care. 2021;9(2):e002480. doi:10.1136/bmjdrc-2021-002480
   Web of Science ®Google Scholar
• Nam YH, Brensinger CM, Bilker WB, et al. Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin. Clin Pharmacol Ther. 2019;105(1):210–218. doi:10.1002/cpt.1146
   Web of Science ®Google Scholar
• Meadows M. Why drugs get pulled off the market. FDA Consum. 2002;36(1):11–17.
   Google Scholar
• Stades AME, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Int Med. 2004;255(2):179–187. doi:10.1046/j.1365-2796.2003.01271.x
   Web of Science ®Google Scholar
• Stacpoole PW, Wright EC, Baumgartner TG, et al. Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med. 1994;97(1):47–54. doi:10.1016/0002-9343(94)90047-7
   Web of Science ®Google Scholar
• Flory JH, Hennessy S, Bailey CJ, Inzucchi SE. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care. 2020;43(1):244–246. doi:10.2337/dc19-0923
   Web of Science ®Google Scholar
• Stage TB, Brøsen K, Christensen MMH. A Comprehensive Review of Drug-Drug Interactions with Metformin. Clin Pharmacokinet. 2015;54(8):811–824. doi:10.1007/s40262-015-0270-6.159
   PubMed Web of Science ®Google Scholar
• May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69–83. doi:10.1177/2042018816638050
   PubMed Web of Science ®Google Scholar
• Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008;57(6):1463–1469. doi:10.2337/db07-1515
   PubMed Web of Science ®Google Scholar
• Choi MK, Jin QR, Ahn SH, et al. Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters. Xenobiotica. 2010;40(12):817–825. doi:10.3109/00498254.2010.520349
   PubMed Web of Science ®Google Scholar
• Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–1258. doi:10.4239/wjd.v6.i13.1246
   PubMed Web of Science ®Google Scholar
• Deshmukh A, Ghannam M, Liang J, et al. Effect of metformin on outcomes of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32(5):1232–1239. doi:10.1111/jce.14954
   PubMed Web of Science ®Google Scholar
• Stoll L, Lo JC. GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D? JACC Basic Transl Sci. 2023;8(8):937–938. doi:10.1016/j.jacbts.2023.03.022
   Google Scholar
• Bohne LJ, Jansen HJ, Dorey TW, et al. Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice. JACC Basic Transl Sci. 2023;8(8):922–936. doi:10.1016/j.jacbts.2023.01.005
   Google Scholar
• Bu Y, Peng M, Tang X, et al. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. J Cell Mol Med. 2022;26(19):4886–4903. doi:10.1111/jcmm.17519
   PubMed Web of Science ®Google Scholar
• Raubenheimer PJ, Cushman WC, Avezum A, et al. Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: a post hoc analysis from the REWIND randomized trial. Diabetes Obes Metab. 2022;24(4):704–712. doi:10.1111/dom.14634
   Web of Science ®Google Scholar
• Wakili R, Voigt N, Kääb S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955–2968. doi:10.1172/JCI46315
   PubMed Web of Science ®Google Scholar
• Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325. doi:10.1152/physrev.00031.2009
   PubMed Web of Science ®Google Scholar
• Yang F, Liu HH, Zhang L, et al. Advanced Glycation End Products Downregulate Connexin 43 and Connexin 40 in Diabetic Atrial Myocytes via the AMPK Pathway. Diabetes Metab Syndr Obes. 2023;16:3045–3056. doi:10.2147/DMSO.S419189
   PubMed Web of Science ®Google Scholar
• Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423–434. doi:10.1093/europace/eun369
   PubMed Web of Science ®Google Scholar
• Goudis CA, Korantzopoulos P, Ntalas IV, et al. Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies. Int J Cardiol. 2015;184(1):617–622.
   Google Scholar
• Michaud GF, Stevenson WG. Atrial Fibrillation. N Engl J Med. 2021;384(4):353–361. doi:10.1056/NEJMcp2023658
   PubMed Web of Science ®Google Scholar
• Li J, Gao M, Zhang M, et al. Treatment of atrial fibrillation: a comprehensive review and practice guide. Cardiovasc J Afr. 2020;31(3):153–158. doi:10.5830/CVJA-2019-064
   Web of Science ®Google Scholar
• Aktas G, Atak Tel BM, et al. Treatment of type 2 diabetes patients with heart conditions. Expert Rev Endocrinol Metab. 2023;18(3):255–265. doi:10.1080/17446651.2023.2204941
   PubMed Web of Science ®Google Scholar
• Qian LL, Liu XY, Li XY, et al. Effects of Electrical Remodeling on Atrial Fibrillation in Diabetes Mellitus. Rev Cardiovasc Med. 2023;24(1):3.
   Web of Science ®Google Scholar
• Snell-Bergeon JK, Wadwa RP. Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technol Ther. 2012;14 Suppl 1(Suppl 1):S51–8. doi:10.1089/dia.2012.0031
   Google Scholar
• Tsujimoto T, Sugiyama T, Noda M, et al. Intensive Glycemic Therapy in Patients With Type 2 Diabetes on β-Blockers. Diabetes Care. 2016;39(10):1818–1826. doi:10.2337/dc16-0721
   Web of Science ®Google Scholar
• Yu O, Azoulay L, Yin H, et al. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Am J Med. 2017;131(3):317.e11–317.e22. doi:10.1016/j.amjmed.2017.09.044
   Web of Science ®Google Scholar
• Akirov A, Grossman A, Shochat T, Shimon I. Hyperglycemia on admission and hospitalization outcomes in patients with atrial fibrillation. Clin Cardiol. 2017;40(11):1123–1128. doi:10.1002/clc.22801
   Web of Science ®Google Scholar
• Yuan M, Gong M, Zhang Z, et al. Hyperglycemia Induces Endoplasmic Reticulum Stress in Atrial Cardiomyocytes, and Mitofusin-2 Downregulation Prevents Mitochondrial Dysfunction and Subsequent Cell Death. Oxid Med Cell Longev. 2020:6569728. doi:10.1155/2020/6569728
   Web of Science ®Google Scholar
• Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg. 2012;12(7):543–550. doi:10.5152/akd.2012.188
   PubMedGoogle Scholar
• Mujović N, Marinković M, Mihajlović M, et al. Risk factor modification for the primary and secondary prevention of atrial fibrillation. Part 1. Kardiol Pol. 2020;78(3):192–202. doi:10.33963/KP.15240
   Google Scholar
• Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221–230. doi:10.1016/S2213-8587(18)30136-0
   PubMed Web of Science ®Google Scholar
• Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2002;44(2):129–146. doi:10.1007/s001250051591
   Web of Science ®Google Scholar
• Zheng DL, Wu QR, Zeng P, et al. Advanced glycation end products induce senescence of atrial myocytes and increase susceptibility of atrial fibrillation in diabetic mice. Aging Cell. 2022;21(12):e13734. doi:10.1111/acel.13734
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol. 2012;157(3):397–402. doi:10.1016/j.ijcard.2011.05.072
   Web of Science ®Google Scholar
• Lee TW, Lee TI, Lin YK, et al. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci. 2021;78:923–934. doi:10.1007/s00018-020-03648-y
   PubMed Web of Science ®Google Scholar
• Fu H. Products (AGEs) and their Receptor Axis in Atrial Fibrillation. Mini Rev Med Chem. 2019;19(13):1040–1048. doi:10.2174/1389557519666190311140737
   Web of Science ®Google Scholar
• Roth GA. Factors, 1990–2019: update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982. doi:10.1016/j.jacc.2020.11.010
   PubMed Web of Science ®Google Scholar
• Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37(5):1344–1350. doi:10.1016/s0735-1097(01)01129-9
   PubMed Web of Science ®Google Scholar
• Triggle CR, Ding H. Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. Acta Physiol (Oxf). 2017;219(1):138–151. doi:10.1111/apha.12644
   Web of Science ®Google Scholar
• Hong J, Zhang Y, Lai S, et al. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care. 2013;36(5):1304–1311. doi:10.2337/dc12-0719
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887–987. doi:10.1016/S2213-8587(17)30317-0
   PubMed Web of Science ®Google Scholar
• Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol. 2009;53(5):373–378. doi:10.1097/FJC.0b013e31819fd4e7
   Web of Science ®Google Scholar
• Riksen NP, Rongen GA. Targeting adenosine receptors in the development of cardiovascular therapeutics. Expert Rev Clin Pharmacol. 2012;5(2):199–218. doi:10.1586/ecp.12.8
   Web of Science ®Google Scholar
• Rankin AC, Brooks R, Ruskin JN, et al. Adenosine and the treatment of supraventricular tachycardia. Am J Med. 1992;92(6):655–664. doi:10.1016/0002-9343(92)90784-9
   Web of Science ®Google Scholar
• Koeppen M, Eckle T, Eltzschig HK. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One. 2009;4(8):e6784. doi:10.1371/journal.pone.0006784
   PubMed Web of Science ®Google Scholar
• Mas M. A Close Look at the Endothelium: its Role in the Regulation of Vasomotor Tone. Eur Urol Suppl. 2009;8(2):48–57. doi:10.1016/j.eursup.2008.10.011
   Web of Science ®Google Scholar
• Domeier TL, Segal SS. Electromechanical and pharmacomechanical signalling pathways for conducted vasodilatation along endothelium of hamster feed arteries. J Physiol. 2007;579(Pt 1):175–186. doi:10.1113/jphysiol.2006.124529
   Web of Science ®Google Scholar
• Dora KA, Lin J, Borysova L, et al. Signaling and structures underpinning conducted vasodilation in human and porcine intramyocardial coronary arteries. Front Cardiovasc Med. 2022;9:980628. doi:10.3389/fcvm.2022.980628
   Web of Science ®Google Scholar
• Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51(7):843–846. doi:10.1053/meta.2002.33349
   PubMed Web of Science ®Google Scholar
• Tsai CM, Kuo HC. Hsu et al Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. Transl Res. 2014;164(6):452–459. doi:10.1016/j.trsl.2014.07.005
   Web of Science ®Google Scholar
• Takahashi N, Shibata R, Ouchi N, et al. Metformin stimulates ischemia-induced revascularization through an eNOS dependent pathway in the ischemic hindlimb mice model. J Vasc Surg. 2015;61(2):489–496. doi:10.1016/j.jvs.2013.09.061
   Web of Science ®Google Scholar
• Ding Y, Zhou Y, Ling P, et al. Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics. 2021;11(19):9376–9396. doi:10.7150/thno.64706
   Web of Science ®Google Scholar
• Triposkiadis F, Xanthopoulos A, Parissis J, et al. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. 2022;27:337–344. doi:10.1007/s10741-020-09987-z
   Web of Science ®Google Scholar
• Haghbin H, Gangwani MK, Ravi SJK, et al. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol. 2020;33(6):603–614. doi:10.20524/aog.2020.0550
   Web of Science ®Google Scholar
• Kim HS, Ren G, Kim T, et al. Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells. Sci Rep. 2020;10:13523. doi:10.1038/s41598-020-70347-w
   Web of Science ®Google Scholar
• Kim JA, Montagnani M, Chandrasekran S, Quon MJ. Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin. 2012;8(4):589–607. doi:10.1016/j.hfc.2012.06.012
   PubMed Web of Science ®Google Scholar
• Lee TI, Kao YH, Chen YC, et al. Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats. Int J Cardiol. 2014;176(1):151–157. doi:10.1016/j.diabres.2013.01.008
   Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A, et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008;29(2):166–176. doi:10.1093/eurheartj/ehm518
   PubMed Web of Science ®Google Scholar
• Kluge MA, Fetterman JL, Vita JA. Mitochondria and endothelial function. Circ Res. 2013;112(8):1171–1188. doi:10.1161/CIRCRESAHA.111.300233
   PubMed Web of Science ®Google Scholar
• Li C, Reif MM, Craige SM, et al. Endothelial AMPK activation induces mitochondrial biogenesis and stress adaptation via eNOS-dependent mTORC1 signaling. Nitric Oxide. 2016;55-56:45–53. doi:10.1016/j.niox.2016.03.003
   PubMed Web of Science ®Google Scholar
• Halling JF, Pilegaard H. PGC-1α-mediated regulation of mitochondrial function and physiological implications. Appl Physiol Nutr Metab. 2020;45(9):927–936. doi:10.1139/apnm-2020-0005
   Web of Science ®Google Scholar
• Khan AA, Thomas GN, Lip GYH, Shantsila A. Endothelial function in patients with atrial fibrillation. Ann Med. 2020;52(1–2):1–11. doi:10.1080/07853890.2019.1711158
   PubMed Web of Science ®Google Scholar
• Freedman JE, Loscalzo J, Barnard MR, et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100(2):350–356. doi:10.1172/JCI119540
   Web of Science ®Google Scholar
• Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15(8):1983–1992. doi:10.1097/01.ASN.0000132474.50966.DA
   PubMed Web of Science ®Google Scholar
• Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106(22):2854–2858. doi:10.1161/01.cir.0000039327.11661.16
   PubMed Web of Science ®Google Scholar
• Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabet Res Clin Pract. 2008;81(1):56–60. doi:10.1016/j.diabres.2008.02.006
   PubMed Web of Science ®Google Scholar
• Carnes CA, Chung MK. Nakayama T, et al Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001;89(6):E32–8. doi:10.1161/hh1801.097644
   Web of Science ®Google Scholar
• Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34(2):255–265. doi:10.1016/s0008-6363(97)00039-4
   PubMed Web of Science ®Google Scholar
• Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107(25):3141–3145. doi:10.1161/01.CIR.0000077912.12202.FC
   PubMed Web of Science ®Google Scholar
• Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449–1459. doi:10.1161/CIRCULATIONAHA.107.722827
   PubMed Web of Science ®Google Scholar
• Bell DSH, Goncalves E. Stroke in the patient with diabetes (Part 2) – prevention and the effects of glucose lowering therapies. Diabet Res Clin Pract. 2020;164. doi:10.1016/j.diabres.2020.108199
   Web of Science ®Google Scholar
• Saez JC, Berthoud VM, Branes MC, et al. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev. 2003;83(4):1359–1400. doi:10.1152/physrev.00007.2003
   PubMed Web of Science ®Google Scholar
• Rodríguez-Sinovas A, Sánchez JA, Valls-Lacalle L, et al. Connexins in the Heart: regulation, Function and Involvement in Cardiac Disease. Int J Mol Sci. 2021;22(9):4413. doi:10.3390/ijms22094413
   PubMed Web of Science ®Google Scholar
• Kelm NQ, Solinger JC, Piell KM, Cole MP. Conjugated Linoleic Acid-Mediated Connexin-43 Remodeling and Sudden Arrhythmic Death in Myocardial Infarction. Int J Mol Sci. 2023;24(13):11208. doi:10.3390/ijms241311208
   Web of Science ®Google Scholar
• Severs NJ, Dupont E, Coppen SR, et al. Remodelling of gap junctions and connexin expression in heart disease. Biochim Biophys Acta. 2004;1662(1–2):138–148. doi:10.1016/j.bbamem.2003.10.019
   Web of Science ®Google Scholar
• Solan JL, Lampe PD. Specific Cx43 phosphorylation events regulate gap junction turnover in vivo. FEBS Lett. 2014;588(8):1423–1429. doi:10.1016/j.febslet.2014.01.049
   PubMed Web of Science ®Google Scholar
• Liu D, He J, Zhou D, et al. Connexin43 Overexpression Exacerbates Myocardial Ischemic Reperfusion Injury in Diabetes via Modulating Cardiac Autophagy. FASEB J. 2022;36(S1):7849. doi:10.1096/fasebj.2022.36.S1.L7849
   Google Scholar
• Ek-Vitorín JF, Pontifex TK, Burt JM. Cx43 Channel Gating and Permeation: multiple Phosphorylation-Dependent Roles of the Carboxyl Terminus. Int J Mol Sci. 2018;19(6):1659. doi:10.3390/ijms19061659
   Web of Science ®Google Scholar
• Remo BF, Qu J, Volpicelli FM, et al. Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circ Res. 2011;108(12):1459–1466. doi:10.1161/CIRCRESAHA.111.244046
   Web of Science ®Google Scholar
• Ozcan C, Battaglia E, Young R, et al. LKB1 knockout mouse develops spontaneous atrial fibrillation and provides mechanistic insights into human disease process. J Am Heart Assoc. 2015;4(3):e001733. doi:10.1161/JAHA.114.001733
   Web of Science ®Google Scholar
• Ozcan C, Li Z, Kim G, et al. Molecular Mechanism of the Association Between Atrial Fibrillation and Heart Failure Includes Energy Metabolic Dysregulation Due to Mitochondrial Dysfunction. J Card Fail. 2019;25(11):911–920. doi:10.1016/j.cardfail.2019.08.005
   PubMed Web of Science ®Google Scholar
• Ozcan C, Dixit G, Li Z. Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation. J Cardiovasc Transl Res. 2021;14(3):492–502. doi:10.1007/s12265-020-10069-6
   Web of Science ®Google Scholar
• Akoyev V, Takemoto DJ. ZO-1 is required for protein kinase C gamma-driven disassembly of connexin 43. Cell Signal. 2007;19(5):958–967. doi:10.1016/j.cellsig.2006.11.007
   Web of Science ®Google Scholar
• Wagner LM, Saleh SM, Boyle DJ, et al. Effect of protein kinase Cgamma on gap junction disassembly in lens epithelial cells and retinal cells in culture. Mol Vis. 2002;8:59–66.
   PubMed Web of Science ®Google Scholar
• Gong Y, Wang C, Jiang Y, et al. Metformin Inhibits Tumor Metastasis through Suppressing Hsp90α Secretion in an AMPKα1-PKCγ Dependent Manner. Cells. 2020;9(1):144. doi:10.3390/cells9010144
   Web of Science ®Google Scholar
• Rhett JM, Ongstad EL, Jourdan J, et al. Cx43 Associates with Nav1.5 in the Cardiomyocyte Perinexus. J Membr Biol. 2012;245(7):411–422. doi:10.1007/s00232-012-9465-z
   Web of Science ®Google Scholar
• Kim GE, Ross JL, Xie C, et al. LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation. Cardiovasc Res. 2015;108(1):197–208. doi:10.1093/cvr/cvv212
   Web of Science ®Google Scholar
• Molaei A, Molaei E, Sadeghnia H, et al. LKB1: an emerging therapeutic target for cardiovascular diseases. Life Sci. 2022;306:120844. doi:10.1016/j.lfs.2022.120844
   PubMed Web of Science ®Google Scholar
• Ndembe G, Intini I, Perin E, et al. LKB1: can We Target an Hidden Target? Focus on NSCLC. Front Oncol. 2022;12:889826. doi:10.3389/fonc.2022.889826
   Web of Science ®Google Scholar
• Pool L, Wijdeveld LFJM, de Groot F, et al. The Role of Mitochondrial Dysfunction in Atrial Fibrillation: translation to Druggable Target and Biomarker Discovery. Int J Mol Sci. 2021;22(16):8463. doi:10.3390/ijms22168463
   PubMed Web of Science ®Google Scholar
• Chen Q, Thompson J, Hu Y, Lesnefsky EJ. Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function. Aging. 2021;13(6):7828–7845. doi:10.18632/aging.202858
   Google Scholar
• Sun D, Yang F. Metformin improves cardiac function in mice with heart failure after myocardial infarction by regulating mitochondrial energy metabolism. Biochem Biophys Res Commun. 2017;486(2):329–335. doi:10.1016/j.bbrc.2017.03.036
   PubMed Web of Science ®Google Scholar
• Larsen AH, Jessen N, Nørrelund H, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail. 2020;22(9):1628–1637. doi:10.1002/ejhf.1656
   PubMed Web of Science ®Google Scholar
• Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18:96. doi:10.1186/s12933-019-0900-7
   PubMed Web of Science ®Google Scholar
• Karnewar S, Neeli PK, Panuganti D, et al. Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: relevance in age-associated vascular dysfunction. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt A):1115–1128. doi:10.1016/j.bbadis.2018.01.018
   PubMed Web of Science ®Google Scholar
• de Marañón AM, Díaz-Pozo P, Canet F, et al. Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. Redox Biol. 2022;53:102342. doi:10.1016/j.redox.2022.102342
   Web of Science ®Google Scholar
• Aatsinki SM, Buler M, Salomäki H, et al. Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions. Br J Pharmacol. 2014;171(9):2351–2363. doi:10.1111/bph.12585
   Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• Bai F, Liu Y, Tu T, et al. Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway. Lipids Health Dis. 2019;18(1):1–9. doi:10.1186/s12944-019-1059-7
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhou L, Novák P, et al. Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: a Potential Target for Diabetic Nephropathy. J Diabetes Res. 2022;2022:2193768. doi:10.1155/2022/2193768
   Web of Science ®Google Scholar
• Yao C, Veleva T, Scott L, et al. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018;138(20):2227–2242. doi:10.1161/CIRCULATIONAHA.118.035202
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Y, Wang Y, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci. 2019;15(5):1010–1019. doi:10.7150/ijbs.29680
   PubMed Web of Science ®Google Scholar
• Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84–93. doi:10.1016/j.yjmcc.2015.12.011
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu T, Ng CY, et al. Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies. Cardiovasc Ther. 2014;32(5):233–241. doi:10.1111/1755-5922.12089
   PubMed Web of Science ®Google Scholar
• Jansen HJ, Bohne LJ, Gillis AM, Rose RA. Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease. Heart Rhythm O2. 2020;1(2):147–159. doi:10.1016/j.hroo.2020.05.002
   Google Scholar
• Yildiz M, Lavie CJ, Morin DP, et al. The complex interplay between diabetes mellitus and atrial fibrillation. Expert Rev Cardiovasc Ther. 2022;20(9):707–717. doi:10.1080/14779072.2022.2115357
   PubMed Web of Science ®Google Scholar
• Ozturk N, Uslu S, Ozdemir S. Diabetes-induced changes in cardiac voltage-gated ion channels. World J Diabetes. 2021;12(1):1–18. doi:10.4239/wjd.v12.i1.1
   PubMed Web of Science ®Google Scholar
• Liu CH, Hua N, Fu X, et al. Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats. BMC Cardiovasc Disord. 2018;18(1):236. doi:10.1186/s12872-018-0950-x
   Google Scholar
• Liu C, Hua N, Fu X, et al. Metformin Regulates the Expression of SK2 and SK3 in the Atria of Rats With Type 2 Diabetes Mellitus Through the NOX4/p38MAPK Signaling Pathway. J Cardiovasc Pharmacol. 2018;72(5):205–213. doi:10.1097/FJC.0000000000000615
   Web of Science ®Google Scholar
• Jichitu A, Bungau S, Stanescu AMA, et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics. 2021;1(4):689. doi:10.3390/diagnostics11040689
   Google Scholar
• Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem. 1991;266(13):8162–8170.
   PubMed Web of Science ®Google Scholar
• Wisneski JA, Stanley WC, Neese RA, et al. Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J Clin Invest. 1990;85(5):1648–1656. doi:10.1172/JCI114616
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–258. doi:10.1152/physrev.00015.2009
   PubMed Web of Science ®Google Scholar
• Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33(5):469–477. doi:10.1007/s10545-010-9061-2
   PubMed Web of Science ®Google Scholar
• Greenwell AA, Gopal K, Ussher JR. Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy. Front Physiol. 2020;11:570421. doi:10.3389/fphys.2020.570421
   Web of Science ®Google Scholar
• Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):H1060–1076. doi:10.1152/ajpheart.00646.2012
   PubMed Web of Science ®Google Scholar
• Ho KL, Zhang L, Wagg C, et al. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019;115(11):1606–1616. doi:10.1093/cvr/cvz045
   PubMed Web of Science ®Google Scholar
• Schugar RC, Moll AR. André d’Avignon D, et al Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab. 2014;3(7):754–769. doi:10.1016/j.molmet.2014.07.010
   Web of Science ®Google Scholar
• Barth AS, Merk S, Arnoldi E, et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res. 2005;96(9):1022–1029. doi:10.1161/01.RES.0000165480.82737.33
   Web of Science ®Google Scholar
• Shingu Y, Yokota T, Takada S, et al. Decreased gene expression of fatty acid binding protein 3 in the atrium of patients with new onset of atrial fibrillation in cardiac perioperative phase. J Cardiol. 2018;71(1):65–70. doi:10.1016/j.jjcc.2017.07.003
   PubMed Web of Science ®Google Scholar
• Shingu Y, Takada S, Yokota T, et al. Correlation between increased atrial expression of genes related to fatty acid metabolism and autophagy in patients with chronic atrial fibrillation. PLoS One. 2020;15(4):e0224713. doi:10.1371/journal.pone.0224713
   PubMed Web of Science ®Google Scholar
• Khawaja O, Bartz TM, Ix JH, et al. Plasma free fatty acids and risk of atrial fibrillation (from the Cardiovascular Health Study). Am J Cardiol. 2012;110(2):212–216. doi:10.1016/j.amjcard.2012.03.010
   Web of Science ®Google Scholar
• Hansen PS, Clarke RJ, Buhagiar KA, et al. Alloxan-induced diabetes reduces sarcolemmal Na+-K+ pump function in rabbit ventricular myocytes. Am J Physiol Cell Physiol. 2007;292(3):C1070–7. doi:10.1152/ajpcell.00288.2006
   Web of Science ®Google Scholar
• Barth AS, Tomaselli GF. Cardiac metabolism and arrhythmias. Circ Arrhythm Electrophysiol. 2009;2(3):327–335. doi:10.1161/CIRCEP.108.817320
   PubMed Web of Science ®Google Scholar
• Bueno-Orovio A, Sánchez C, Pueyo E, Rodriguez B. Na/K pump regulation of cardiac repolarization: insights from a systems biology approach. Pflugers Arch. 2014;466(2):183–193. doi:10.1007/s00424-013-1293-1
   PubMed Web of Science ®Google Scholar
• Lenski M, Schleider G, Kohlhaas M, et al. Arrhythmia causes lipid accumulation and reduced glucose uptake. Basic Res Cardiol. 2015;110(4):40. doi:10.1007/s00395-015
   Web of Science ®Google Scholar
• Dai DF, Chen T, Johnson SC, et al. Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal. 2012;16(12):1492–1526. doi:10.1089/ars.2011.4179
   Web of Science ®Google Scholar
• van Rosendael AR, Dimitriu-Leen AC, van Rosendael PJ, et al. Association Between Posterior Left Atrial Adipose Tissue Mass and Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2017;10(2):e004614. doi:10.1161/CIRCEP.116.004614
   Web of Science ®Google Scholar
• Sutanto H, Lyon A, Lumens J, et al. Cardiomyocyte calcium handling in health and disease: insights from in vitro and in silico studies. Prog Biophys Mol Biol. 2020;157:54–75. doi:10.1016/j.pbiomolbio.2020.02.008
   Web of Science ®Google Scholar
• Liu GZ, Hou TT, Yuan Y, et al. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway. Br J Pharmacol. 2016;173(6):1095–1109. doi:10.1111/bph.13438
   PubMed Web of Science ®Google Scholar
• Ludhwani D, Wieters JS. Paroxysmal Atrial Fibrillation; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535439/. Accessed June 10, 2024.
   Google Scholar
• Liu Y, Bai F, Liu N, et al. The Warburg effect: a new insight into atrial fibrillation. Clin Chim Acta. 2019;499:4–12. doi:10.1016/j.cca.2019.08.029
   PubMed Web of Science ®Google Scholar
• Hiraoka M, Okamoto Y, Sano T. Electrophysiological effects of lactates in mammalian ventricular tissues. J Electrocardiol. 1981;14(1):13–20. doi:10.1016/s0022-0736(81)80023-4
   Web of Science ®Google Scholar
• Saman S, Opie LH. Mechanism of reduction of action potential duration of ventricular myocardium by exogenous lactate. J Mol Cell Cardiol. 1984;16(7):659–662. doi:10.1016/s0022-2828(84)80629-x
   Web of Science ®Google Scholar
• Wu P, Zhu T, Huang Y, et al. Current understanding of the contribution of lactate to the cardiovascular system and its therapeutic relevance. Front Endocrinol (Lausanne). 2023;14:1205442. doi:10.3389/fendo.2023.1205442
   Web of Science ®Google Scholar
• Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485(7400):661–665. doi:10.1038/nature11066
   PubMed Web of Science ®Google Scholar
• Muzurović EM, Vujošević S, Mikhailidis DP. Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes? J Cardiovasc Pharmacol Ther. 2021;26(5):415–436. doi:10.1177/10742484211006997
   PubMed Web of Science ®Google Scholar
• Su JR, Lu ZH, Su Y, et al. Relationship of Serum Adiponectin Levels and Metformin Therapy in Patients with Type 2 Diabetes. Horm Metab Res. 2016;48(2):92–98. doi:10.1055/s-0035-1569287
   PubMed Web of Science ®Google Scholar
• Macheret F, Bartz TM, Djousse L, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart. 2015;101(17):1368–1374. doi:10.1136/heartjnl-2014-307015
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Nederlof R, Zuurbier CJ, et al. Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;2(8):615–623. doi:10.1016/S2213-8587(15)00121-7
   Google Scholar